4D Molecular Therapeutics, Inc.

FDMT · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$161-$101-$107-$71
Dep. & Amort.$7$6$4$3
Deferred Tax$0$0$0$0
Stock-Based Comp.$26$20$0$14
Change in WC$1$1-$1-$16
Other Non-Cash-$7-$1$18$1
Operating Cash Flow-$135-$76-$87-$69
Investing Activities
PP&E Inv.-$4-$3-$12-$9
Net Acquisitions$0$0$0$9
Inv. Purchases-$468-$55-$153-$169
Inv. Sales/Matur.$169$0$148$5
Other Inv. Act.$0$173$0-$9
Investing Cash Flow-$302$116-$17-$173
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$331$148$3$114
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$6$8$0$4
Financing Cash Flow$337$157$3$118
Forex Effect$0$0$0$0
Net Chg. in Cash-$100$197-$101-$124
Supplemental Information
Beg. Cash$249$52$153$277
End Cash$149$249$52$153
Free Cash Flow-$138-$79-$98-$78
4D Molecular Therapeutics, Inc. (FDMT) Financial Statements & Key Stats | AlphaPilot